227 related articles for article (PubMed ID: 34343940)
1. PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer.
Chen H; Jiang T; Lin F; Guan H; Zheng J; Liu Q; Du B; Huang Y; Lin X
Int Immunopharmacol; 2021 Oct; 99():107929. PubMed ID: 34343940
[TBL] [Abstract][Full Text] [Related]
2. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
[TBL] [Abstract][Full Text] [Related]
3. Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
Cai X; Wei B; Li L; Chen X; Liu W; Cui J; Lin Y; Sun Y; Xu Q; Guo W; Gu Y
Int Immunopharmacol; 2020 Nov; 88():106858. PubMed ID: 32795895
[TBL] [Abstract][Full Text] [Related]
4. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.
Kim W; Chu TH; Nienhüser H; Jiang Z; Del Portillo A; Remotti HE; White RA; Hayakawa Y; Tomita H; Fox JG; Drake CG; Wang TC
Gastroenterology; 2021 Feb; 160(3):781-796. PubMed ID: 33129844
[TBL] [Abstract][Full Text] [Related]
5. Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.
Zhao S; Ren S; Jiang T; Zhu B; Li X; Zhao C; Jia Y; Shi J; Zhang L; Liu X; Qiao M; Chen X; Su C; Yu H; Zhou C; Zhang J; Camidge DR; Hirsch FR
Cancer Immunol Res; 2019 Apr; 7(4):630-643. PubMed ID: 30755403
[TBL] [Abstract][Full Text] [Related]
6. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model.
Wu J; Zhao X; Sun Q; Jiang Y; Zhang W; Luo J; Li Y
Biomed Pharmacother; 2020 May; 125():109746. PubMed ID: 32106386
[TBL] [Abstract][Full Text] [Related]
7. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
9. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
10. Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma.
Yang Y; Wang C; Sun H; Jiang Z; Zhang Y; Pan Z
Cancer Gene Ther; 2021 Feb; 28(1-2):89-97. PubMed ID: 32533100
[TBL] [Abstract][Full Text] [Related]
11. Apatinib Combined with Local Irradiation Leads to Systemic Tumor Control via Reversal of Immunosuppressive Tumor Microenvironment in Lung Cancer.
Liang LJ; Hu CX; Wen YX; Geng XW; Chen T; Gu GQ; Wang L; Xia YY; Liu Y; Fei JY; Dong J; Zhao FH; Ahongjiang Y; Hui KY; Jiang XD
Cancer Res Treat; 2020 Apr; 52(2):406-418. PubMed ID: 31476848
[TBL] [Abstract][Full Text] [Related]
12. Camptothecin enhances the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma.
Wang H; Gao C; Li X; Chen F; Li G
Sci Rep; 2024 Mar; 14(1):7140. PubMed ID: 38532022
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
14. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
15. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
Liang Y; Wang W; Zhu X; Yu M; Zhou C
Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Effects of Nanoscale CaO
Wang Y; Ju S; Zhou H; Bai Y; Zhou C; Liu J; Dong X; Zheng C
Int J Nanomedicine; 2024; 19():137-154. PubMed ID: 38196507
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of combined treatment with pirfenidone and PD-L1 inhibitor in mice bearing ectopic bladder cancer xenograft].
Chen S; Zhang S; Fan W; Sun W; Liu B; Liu J; Guo Y
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Feb; 44(2):210-216. PubMed ID: 38501405
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
20. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
